Condition: Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) · Sponsor: Stingray Therapeutics
This is an open-label, dose escalation and expansion, multi-center phase 2 study evaluating the safety and efficacy of SR-8541A administered orally in combination with intravenous botensilimab and balstilimab in subjects with MSS-CRC with and without active liver metastases.
This description comes directly from the study's public registry record.
Sunil Sharma, MD · 602-343-8402 · ssharma@honorhealth.com
Jonathan Northrup · (317) 517-9500 · jon@stingraytx.com
Always discuss trial participation with your own doctor first.
| Atlantic Health | Morristown, New Jersey, United States | Recruiting |
| Texas Oncology- Austin | Austin, Texas, United States | Recruiting |
| Texas Oncology- Sammons- DFW | Dallas, Texas, United States | Recruiting |
| The University of Texas M.D. Anderson Cancer Center GI Medical Oncology Dept | Houston, Texas, United States | Recruiting |
| Texas Oncology- Northeast Texas | Tyler, Texas, United States | Recruiting |
| Swedish | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06589440